What Retatrutide’s new Phase 3 results actually show—and why this triple agonist remains investigational, unapproved and inappropriate for self-directed use.

What BPC-157 recovery research actually shows—animal findings, limited human evidence, FDA concerns, safety unknowns and anti-doping status.

What GHK-Cu research supports for topical skin use—and why cosmetic evidence should not be stretched into injectable or systemic rejuvenation claims.

Matrixyl and Argireline are popular topical peptides for fine lines, but the evidence supports modest cosmetic benefits—not “Botox in a bottle.” Here is what controlled human studies show, what remains uncertain, and how to evaluate a product safely.

What Epitalon’s circadian, sleep and telomere research actually shows—and why current evidence does not support confident anti-aging or insomnia claims.